The Effects of Pentoxifylline on PAI-1 in an Obese Population
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
PAI-1 is elevated in obese individuals. TNF-alpha, an inflammatory mediator is believed to
play a role in obesity mediated elevations in PAI-1 levels. TNF-alpha blockade with
antibodies and the drug pentoxifylline have been shown to lower PAI-1 levels in animal
models. This study tests the hypothesis that pentoxifylline will lower PAI-1 levels in human
subjects.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center